Long-term safety of dexamethasone sodium phosphate encapsulated in autologous erythrocytes in pediatric patients with ataxia telangiectasia by Mary Kay Koenig, Vincenzo Leuzzi, Riadh Gouider, Riadh Gouider, Eppie M. Yiu, Eppie M. Yiu, Barbara Pietrucha, Asbjørg Stray-Pedersen, Susan L. Perlman, Steve Wu, Trudy Burgers, Rupam Borgohain, Rukmini Mridula Kandadai, Isabelle Meyts, Giorgia Bucciol, Anaita Udwadia-Hegde, Ravi Yadav, Donna Roberts, Aaron Dane, Maureen Roden, Dirk Thye, Biljana Horn, Howard M. Lederman, William P. Whitehouse

“…BackgroundDexamethasone sodium phosphate (DSP) encapsulated in autologous erythrocytes (EryDex) was developed as an alternative to standard glucocorticoids in an effort to eliminate chronic steroid toxicity while preserving efficacy. The primary objective of this report is to describe the safety of long-term use of EryDex in treatment of pediatric patients with ataxia telangiectasia.MethodsThis is a post-hoc analysis of patients treated with EryDex for a minimum of 24 months in two prospective clinical trials. …”
Get full text

First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors by Ignacio I Wistuba, Mamta Kalra, Linus Backert, Martin Wermke, Edwin R Parra, Jason John Luke, Apostolia M Tsimberidou, Sebastian Bunk, Mohammad B Hossain, Andrea Mayer-Mokler, Arun Satelli, Norbert Hilf, Steffen Walter, Cedrik M Britten, Van K Morris, Tobias A W Holderried, Winfried H Alsdorf, Katrin Wetzko, Borje S Andersson, Sandra Grund-Gröschke, Katrin Aslan, Anantha Marisetty, Swapna Satam, Jens Hukelmann, M Alper Kursunel, Karine Pozo, Andreas Acs, Melissa Baumeister, Claudia Wagner, Oliver Schoor, Ali S Mohamed, Delfi Krishna

“…We investigated the safety and tolerability of IMA202 in a first-in-human, dose escalation basket trial in human leucocyte antigen A*02:01 positive patients with melanoma-associated antigen A1 (MAGEA1)-positive advanced solid tumors.Trial design The 2+2 trial design was an algorithmic design based on a maximally acceptable dose-limiting toxicity (DLT) rate of 25% and the sample size was driven by the algorithmic design with a maximum of 16 patients. …”
Get full text

Dipropyl phthalate induces craniofacial chondrogenic defects in zebrafish embryos by Qinyuan Shen, Weitao Hu, Fasheng Liu, Si Dong, Xinya Peng, Yihang Zhong, Chao Chen, Yuhua Zuo, Chenkai Ge, Weirong Li, Wenwen Zha, Zhijun Ye, Zigang Cao, Lan Liao

“…The present study demonstrates that DPRP induces developmental toxicity of zebrafish craniofacial cartilage, which may have adverse effects on other aquatic organisms and humans.…”
Get full text

Spatial-temporal distribution of phytoplankton HAB species and contamination status of oyster toxins under intensive oyster farming in Jiangmen coasts, the South China Sea by Jian Zou, Yayuan Xiao, Jiaqi Su, Yang Liu, Peng Wu, Teng Wang, Lin Lin, Chunhou Li, Yu Liu, Yong Liu

“…The total average abundances of toxic HAB species were 269, 265, 321 and 2.6 × 103 cells L−1 in winter, spring, summer and autumn, respectively. …”
Get full text

Effect of Berberine on the Inflammatory Response of ANA-1 Cells Induced by Angiotensin Ⅱ Based on TLR4 Signaling Pathway by GAO Dexing, JIA Peizhi, PENG Jun, LIN Wei

“…Cell proliferation and toxicity test (CCK-8) was used to detect the effect of different concentrations of BBR on cell viability; the flow cytometry was used to detect the mean fluorescence intensity (MFI) of TLR4 on cell membrane ; ELISA method was used to detect the content of interleukin-1β (IL-1β), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α); the real-time quantitative PCR was used to detect the mRNA level of IL-1β, IL-6, TNF-α; Western blot was used to detect the phosphorylation of p-ERK/ERK, p-p38/p38, p-JNK/JNK, p-p65/p65 and p-IRF3/IRF3 and the expression of TLR4, MyD88 and AP-1; the biochemical assay was used to detect the content of malondialdehyde (MDA) and the activity of superoxide dismutase (SOD).Results① CCK-8 assay results: compared with the control group, there was no significant difference in cell activity of the low, medium and high- dose BBR group, the difference was not statistically significant (<italic>P</italic>&gt;0.05). ② Flow cytometry results: compared with the fluorescent antibody group, MFI of the model group was significantly decreased; compared with the model group, MFI of the model group + the high dose BBR group was significantly increased, the difference was statistically significant (<italic>P</italic>&lt;0.05). ③ ELISA results: compared with the control group, the content of IL-1β, IL-6, TNF- α of the model group was significantly increased; compared with the model group, the content of IL-1β, IL-6, TNF- α of the model group + the low, medium and high dose BBR group was significantly decreased, the difference was statistically significant (<italic>P</italic>&lt;0.05). ④ Real-time quantitative PCR results: compared with the control group, the mRNA level of IL-1β, IL-6, TNF-α of the model group was significantly increased; compared with the model group, the mRNA level of IL-1β, IL-6, TNF- α of the model group + the low, medium and high-dose BBR group was significantly decreased, the difference was statistically significant (<italic>P</italic>&lt;0.05). ⑤ Western blot results: compared with the control group, the phosphorylation expression of p65 and IRF-3 protein of the model group after intervention for 45 minutes was significantly increased, and the phosphorylation expression of p65, IRF-3 protein in the model group + the low, medium and high-dose BBR group was significantly decreased. …”
Get full text

Phase I study of intratumoral administration of CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or ade... by Lucie Heinzerling, Michael Fluck, Caroline Robert, Celeste Lebbe, Erika Richtig, Sven D Koch, Ulrike Gnad-Vogt, Tobias Seibel, Thomas Eigentler, Juan Martin-Liberal, Sebastian Ochsenreither, Peter Mohr, Patrick Terheyden, Carsten Weishaupt, Michael Erdmann, Lukas Koch, Ainara Soria, Igor Samoylenko, Jürgen Krauß, Peter Brossart, Franz Georg Bauernfeind, Marina Gonzalez, Peter Wengenmayer, Ioannis Thomas, Artem Poltoratskiy, Marina Sekacheva, Beate Schmitt-Bormann, Gianluca Quintini, Martin Falk, Paula Codó, Arjun Oberoi, Jana Hess, Yulia Semiletova, Casilda Llacer Perez, Oliver Schönborn-Kellenberger

“…Two patients in the CV8102 monotherapy dose escalation cohort experienced relevant toxicities at the 900 µg dose level. One patient had Grade 3 aspartate transaminase/alanine aminotransferase elevation which met dose-limiting toxicity (DLT) criteria. …”
Get full text

Outcomes with bridging radiation therapy prior to chimeric antigen receptor T-cell therapy in patients with aggressive large B-cell lymphomas by Gohar S. Manzar, Chelsea C. Pinnix, Stephanie O. Dudzinski, Kathryn E. Marqueen, Elaine E. Cha, Lewis F. Nasr, Alison K. Yoder, Michael K. Rooney, Paolo Strati, Sairah Ahmed, Chijioke Nze, Ranjit Nair, Luis E. Fayad, Michael Wang, Loretta J. Nastoupil, Jason R. Westin, Christopher R. Flowers, Sattva S. Neelapu, Jillian R. Gunther, Bouthaina S. Dabaja, Susan Y. Wu, Penny Q. Fang

“…Clinical/treatment characteristics, response, and toxicity were extracted. Survival was modeled using Kaplan-Meier or Cox regression models for events distributed over time, or binary logistic regression for disease response. …”
Get full text

Endocrine disruptors and cancers. [Perturbateurs endocriniens et cancers] by Souhila AOUICHAT BOUGUERRA, Saliha BOUMAZA, Khouloud HEMILA, Samia NEGGAZI, Nadjiba HAMLAT, Sihem BERDJA, Leïla SMAIL, Besma MOHAMMEDI, Kenza REGUOUAT, Amina BOUDJLIDA, Sofiane KACI, Fatima BOUACHRIA-BOUSMAHA

“…These compounds are present in our environment, carried by air, water, soil and their toxicity is proven because they interact with the hormones synthesis, degradation, transport and mode of action. …”
Get full text

Applied pharmacogenetics to predict response to treatment of first psychotic episode: study protocol by Sergi Mas, Sergi Mas, Sergi Mas, Laura Julià, Manuel J. Cuesta, Manuel J. Cuesta, Manuel J. Cuesta, Benedicto Crespo-Facorro, Benedicto Crespo-Facorro, Benedicto Crespo-Facorro, Benedicto Crespo-Facorro, Javier Vázquez-Bourgon, Javier Vázquez-Bourgon, Javier Vázquez-Bourgon, Carlos Spuch, Carlos Spuch, Ana Gonzalez-Pinto, Ana Gonzalez-Pinto, Angela Ibañez, Angela Ibañez, Judith Usall, Judith Usall, Cristina Romero-López-Alberca, Cristina Romero-López-Alberca, Ana Catalan, Ana Catalan, Ana Catalan, Ana Catalan, Ana Catalan, Anna Mané, Anna Mané, Anna Mané, Anna Mané, Miquel Bernardo, Miquel Bernardo, Miquel Bernardo, Miquel Bernardo

“…The application of personalized medicine in patients with first-episode psychosis (FEP) requires tools for classifying patients according to their response to treatment, considering both treatment efficacy and toxicity. However, several limitations have hindered its translation into clinical practice. …”
Get full text

Panitumumab versus cetuximab in combination with irinotecan in refractory metastatic colorectal cancer by Maria Ignez Freitas Melro Braghiroli, Daniel Santos Rocha Sobral Filho, Juliana Goes Martins Fagundes, Elizabeth Zambrano Mendoza, Maria Fernanda Batistuzzo Vicentini Neffa, Karla Souza Campos, Leonardo Gomes da Fonseca, Renata Colombo Bonadio, Aley Talans, Oddone Freitas Melro Braghiroli, Maria Cecília Mathias-Machado, Jorge Sabbaga, Camila Motta Venchiarutti Moniz, Paulo Marcelo Gehm Hoff

“…The secondary outcomes were objective response rate, stratified by primary tumor sidedness, progression-free survival, and toxicity. Results: This analysis included 412 patients who had progressed on irinotecan and were KRAS wild-type. …”
Get full text

Supercharged nanoadhesive through co-assembly of recombinant protein and tetrahedral DNA for corneal transplantation by Jing Zhao, Feng Zhang, Zhe Zhang, Zhenhua Li, Yanze Yu, Bingqing Sun, Binghong Yu, Yong Ma, Xuan Ding, Liyin Wang, Lifei Zheng, Wenguo Cui, Xingtao Zhou

“…A major challenge is achieving rapid adhesion without introducing polymer barriers or chemical toxicity from cross-linking. To address this, we developed a novel cornea-specific nanoadhesive constructed through protein-DNA co-assembly and applied it to corneal transplantation. …”
Get full text

Hybridization-based discovery of novel quinazoline-2-indolinone derivatives as potent and selective PI3Kα inhibitors by Changqun Liu, Yuening Cao, Yi Zuo, Chaozheng Zhang, Senmiao Ren, Xin Zhang, Chuanqi Wang, Yingjie Zeng, Jie Ling, Yilan Liu, Zixian Chen, Xiujun Cao, Zhengzhi Wu, Chuantao Zhang, Jun Lu

“…Importantly, compound 8 demonstrated potent in vivo anti-tumor activity in non-small cell lung cancer mouse models without visible toxicity. Conclusions: This study presented a new avenue for the development of PI3Kα inhibitors and provided a solid foundation for novel QHIDs as potential future therapies for the treatment of NSCLC.…”
Get full text

Development of a framework to structure decision-making in environmental and occupational health: A systematic review and Delphi study by Emily Senerth, Paul Whaley, Elie Akl, Brandy Beverly, Pablo Alonso-Coello, Ezza Jalil, Jayati Khattar, Nicole R. Palmer, Andrew Rooney, Holger J. Schünemann, Kristina A. Thayer, Katya Tsaioun, Rebecca L. Morgan

“…We identified several differences between decision criteria that are applied in EOH and the GRADE EtD framework, including vocabulary that is specific to EOH (e.g., toxicity, the precautionary principle), and granularity of the EOH decision considerations (e.g., detailed signaling questions to assess feasibility and resources required). …”
Get full text

Effective cancer immunotherapy combining mRNA-encoded bispecific antibodies that induce polyclonal T cell engagement and PD-L1-dependent 4-1BB costimulation by Oana Hangiu, Oana Hangiu, Oana Hangiu, Rocío Navarro, Susana Frago, Laura Rubio-Pérez, Laura Rubio-Pérez, Laura Rubio-Pérez, Antonio Tapia-Galisteo, Antonio Tapia-Galisteo, Antonio Tapia-Galisteo, Laura Díez-Alonso, Laura Díez-Alonso, Laura Díez-Alonso, Marina Gómez-Rosel, Marina Gómez-Rosel, Marina Gómez-Rosel, Noelia Silva-Pilipich, Noelia Silva-Pilipich, Lucía Vanrell, Cristian Smerdou, Cristian Smerdou, Kenneth A. Howard, Laura Sanz, Luis Álvarez-Vallina, Luis Álvarez-Vallina, Luis Álvarez-Vallina, Marta Compte

“…When administered as a mRNA-LNP combination (ComboRNA), the growth of EGFR-positive tumors in immunocompetent mice was significantly inhibited, resulting in tumor regression in 20% of cases with no associated toxicity. Histological analysis confirmed increased T cell infiltration in the tumors treated with LITERNA and ComboRNA. …”
Get full text

Implementing a nurse-enabled, integrated, shared-care model involving specialists and general practitioners in early breast cancer post-treatment follow-up (EMINENT): a single-cent... by Raymond J. Chan, Fiona Crawford-Williams, Chad Yixian Han, Lee Jones, Alexandre Chan, Daniel McKavanagh, Marissa Ryan, Christine Carrington, Rebecca L. Packer, Megan Crichton, Nicolas H. Hart, Emma McKinnell, Melissa Gosper, Juanita Ryan, Bethany Crowe, Ria Joseph, Carolyn Ee, Jane Lee, Steven M. McPhail, Katharine Cuff, Laisa Teleni, Jon Emery

“…Feasibility and effectiveness outcome measures, including health-related quality of life (primary outcome), physical activity and nutrition, patient experience, and financial toxicity were collected at baseline, and at 3-, 6-, and 12-months, with health service utilisation data at 24-months. …”
Get full text

Intratumoral pan-ErbB targeted CAR-T for head and neck squamous cell carcinoma: interim analysis of the T4 immunotherapy study by Fiona Reid, Sophie Papa, John Maher, Jean-Pierre Jeannon, James Spicer, Victoria Gibson, Selvam Thavaraj, Michael Metoudi, Christopher Fisher, Nicholas Beckley-Hoelscher, Andrew Hope, Maria Elstad, Antonella Adami, Richard Beatson, Molly Sarah George, Daniela Achkova, Evangelia Williams, Sefina Arif, Abdel Douri, Marc Delord, Mike Lyne, Dharshene Shivapatham, Sakina Gooljar, Arindam Mitra, Linda Gomm, Cienne Morton, Rhonda Henley-Smith, Alice Santambrogio, Cynthia Andoniadou, Sarah Allen, Gary J R Cook, Ana C Parente-Pereira, David M Davies, Farzin Farzaneh, Anna Schurich, Teresa Guerrero-Urbano

“…Treatment-related adverse events were all grade 2 or less, with no dose-limiting toxicities (Common Terminology Criteria for Adverse Events V.4.0). …”
Get full text

Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y glo... by Mieke Van Hemelrijck, Salvatore Grisanti, Avinash Aujayeb, Martin Forster, Giannis Mountzios, Andrea Napolitano, Bruno Vincenzi, Joachim G J V Aerts, Marina Garassino, Valter Torri, Solange Peters, Alex Friedlaender, Alfredo Addeo, Giuseppe Lo Russo, Roberto Ferrara, Diego Signorelli, Alessandro Russo, So Yeon Kim, Jarushka Naidoo, Scott Gettinger, Heather Wakelee, Martin Sebastian, Mark Awad, Abdul Rafeh Naqash, Alessio Cortellini, Raffaele Giusti, Michele De Tursi, Federica Zoratto, Marco Russano, Rita Chiari, Biagio Ricciuti, Andrea De Giglio, Alain Gelibter, Giuseppe Tonini, Amin H Nassar, Alessandra Curioni-Fontecedro, Eleni Karapanagiotou, Emilio Bria, Jack Bell, Paolo Bironzo, Joao V Alessi, Alessandro Morabito, David J Pinato, Francesco Passiglia, Carlo Genova, Francesca Mazzoni, Alessandro Inno, Francesco Grossi, Luca Cantini, Lorenza Landi, Luigi Della Gravara, Margarita Majem, Uma Mukherjee, Federica Biello, Alessandro Leonetti, Annalisa Guida, Marianna Macerelli, Gabriele Minuti, Giulio Metro, Thomas Newsom-Davis, Eleni Josephides, Andrea Camerini, Elisa Roca, David O’Reilly, Mingjia Li, Laura Mezquita, Teresa Gorría, Claudia A M Fulgenzi, Lauren Young, Joel W Neal, Javier Baena, Francesco Pantano, Jacobo Rogado, Mary Jo Fidler, Teresa Beninato, Federica Pecci, Alessandro Di Federico, Kazuki Takada, Leonardo Brunetti, Talal El Zarif, Laura Moliner, Alberto Servetto, Sukumar Kalvapudi, Sai Yendamuri, Edoardo Garbo, Giuseppina Rita Di Fazio, Monica Loza, Ritujith Jayakrishnan, Michele Montrone, Nichola O Awosika, Bartlomiej Tomasik, Maximilian Rost, Isabelle Monnet, Francesco Agustoni, Artur Katz, Dwight Hall Owen, Michele Ghidini, Armida D’Incecco, Gianpaolo Spinelli, Monica Verrico, Manuel Dupont, Rafael Di Marco Barros, Diego Luigi Cortinovis, Chiara Bennati, Frank Aboubakar Nana, Anne-Marie Dingemans, Taher Abu Hejleh

“…By the data cut-off, 1015 patients (96.7%) had permanently discontinued treatment: 659 (64.9%) due to progressive disease, 156 (15.4%) due to toxicity, 77 (7.6%) due to treatment completion, and 106 (10.4%) due to other reasons. …”
Get full text

Liver morphometry and histopathology effects in Astyanax lacustris exposed to lambda-cyhalothrin pyrethroid insecticide by Tiago Venancio da Silva, André Luiz do Nascimento Silva, Karine Nathiele Nogueira Farias, Carla Leticia Gediel Rivero Wendt, Lucas de Oliveira Brasileiro, Edilaine Fogaça, Sabrina Fuzer Gonçalves, Brenda de Oliveira Martins, Maria Eduarda Corona Garcia, Lilian Franco-Belussi, Carlos Eurico S. Fernandes

“…Lambda-cyhalothrin (LC) is a pyrethroid insecticide employed to manage various arthropods as an alternative to persistent insecticides with minimized toxic effects on birds and mammals. However, LC causes oxidative and neurotoxic damages in fish Danio rerio. …”
Get full text

Targeting p62 by sulforaphane promotes autolysosomal degradation of SLC7A11, inducing ferroptosis for osteosarcoma treatment by Qiuming Zou, Xiaofeng Zhou, Jianqin Lai, Haixia Zhou, Jinxuan Su, Zhijing Zhang, Xiaosong Zhuang, Lili Liu, Ruijie Yuan, Sijia Li, Siyu Yang, Xinyi Qu, Jiezhu Feng, Yongqi Liu, Zisheng Li, Shiting Huang, Zhi Shi, Yu Yan, Zhiming Zheng, Wencai Ye, Qi Qi

“…Sulforaphane (SFN), the main bioactive compound derived from cruciferous vegetables, has shown potential anti-cancer effects with negligible toxicity. However, the role of ferroptosis in the effect of SFN on OS remains unknown. …”
Get full text

Bisphenol B restrains rat leydig cell function via H3K27me3/H3K9me3 histone modifications by Jiayi He, Huiqian Zhang, Hehua Quan, Qingyuan Wang, Congcong Wen, Yiyan Wang, Yang Zhu, Ren-Shan Ge, Xiaoheng Li

“…The findings of the study indicate the involvement of histone methylation (H3K27me3) in BPB-induced steroidogenic dysfunction, emphasizing the correlation between histone modifications and male reproductive toxicity.…”
Get full text